FDA.reportPublic FDA data

Dalvance

RxCUI
1539244
RxNorm name
Dalvance
Term type
BN
Status
Active
Updated
2026-09-25 04:22:38

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
072014
Active start
072014
Multiple ingredient
NO
Branded
YES

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
dalbavancin1539239

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRDalvance1NAMES
RxNorm NameDalvance1NAMES
TTYBN1ATTRIBUTES
RxCUI15392441CODES
MMSL_CODEBN2213161CODES

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 0 matching rows.

No records found.

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCJ01XAGlycopeptide antibacterialsATC1-4dalbavancin
FDASPLD000077427LipoglycopeptidesCHEMhas_chemical_structuredalbavancin
FDASPLN0000191281Lipoglycopeptide AntibacterialEPChas_epcdalbavancin
MEDRTD017334TeicoplaninCHEMhas_ingredientdalbavancin
MEDRTD004342Drug HypersensitivityDISEASEci_withdalbavancin
MEDRTD012874Skin Diseases, InfectiousDISEASEmay_treatdalbavancin
MEDRTD013203Staphylococcal InfectionsDISEASEmay_treatdalbavancin
MEDRTD013290Streptococcal InfectionsDISEASEmay_treatdalbavancin
MEDRTN0000000150Protein Synthesis InhibitorsMOAhas_moadalbavancin
MEDRTN0000008479Decreased Cell Wall Synthesis & RepairPEhas_pedalbavancin

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESBN_CARDINALITYsingle
ATTRIBUTESGENERAL_CARDINALITYSINGLE
ATTRIBUTESRXNAV_HUMAN_DRUGUS
SOURCESSourceMultum MediSource Lexicon